Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | GAA | P10253 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | CASP7 | P55210 | 2/20 | 0.67 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | BPTF | Q12830 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12908874 | 0.85 | MAPT (0.59) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL25795537 | 0.80 | L3MBTL1 (0.46) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL17194236 | 0.80 | MAPT (1.00) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL17194349 | 0.80 | ALDH1A1 (0.62) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL17194172 | 0.80 | ALDH1A1 (1.00) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL3421133 | 0.78 | BPTF (1.00) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL4035961 | 0.76 | BPTF (0.78) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL2960241 | 0.76 | BPTF (0.72) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL2960524 | 0.75 | BPTF (0.70) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL13366491 | 0.74 | BPTF (0.72) | MAPTALDH1A1KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875615-A | Methoxybenzyl urea compound and application thereof | 济南大学 | 2020-11-03 | — | — | CN | claimed |
| CN-111875615-A | Methoxybenzyl urea compound and application thereof | 济南大学 | 2020-11-03 | — | — | CN | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-6387912-B1 | STROKE THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6222034-B1 | AS SEROTININ RECEPTOR ANTAGONISTS; FOR THERAPY OF DEPRESSION, CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | MAPT 1389/4885ALDH1A1 566/4885KDM4E 1608/4885 |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | MKI67, CCNT1, RB1 | MAPT 884/4885ALDH1A1 546/4885KDM4E 2213/4885 |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | UGDH, G6PD, DPYD | MAPT 2722/4885ALDH1A1 54/4885KDM4E 1051/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | MAPT 1276/4885ALDH1A1 615/4885KDM4E 1697/4885 |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | MAPT 3705/4885ALDH1A1 467/4885KDM4E 2362/4885 |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, BAD | MAPT 1192/4885ALDH1A1 683/4885KDM4E 1628/4885 |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | BCL2, BAX, MCL1 | MAPT 1411/4885ALDH1A1 297/4885KDM4E 1672/4885 |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | MKI67, BCL2, BAX | MAPT 2223/4885ALDH1A1 576/4885KDM4E 2046/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | MAPT 1402/4885ALDH1A1 317/4885KDM4E 1813/4885 |
| US-20070259911-A1 | Novel Compounds and Use of Tetrahydropyridothiophenes | RB1, BAX, BCL2 | MAPT 2055/4885ALDH1A1 412/4885KDM4E 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.